Vikram Malhi is a Principal Scientist at Genentech, where they have worked since 2009, contributing extensively to clinical pharmacology and the development of oncology drugs. They played a key role in obtaining approvals from global health authorities for Genentech's first small molecule, Erivedge, and have progressed from research associate to their current position over the years. Vikram previously held the role of Associate Scientist at Biogen Idec in 2008, focusing on process development. They earned a Bachelor of Science in Bioengineering, Biotechnology from UC San Diego, after completing their education at The Harker School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices